Renoprotection for TAVI-Patients with renal dysfunction through remote ischemic preconditioning (rIPC)
Phase 2
Recruiting
- Conditions
- N14.2Chronic kidney disease, unspecifiedN18.9Nephropathy induced by unspecified drug, medicament or biological substance
- Registration Number
- DRKS00017553
- Lead Sponsor
- niversitätsmedizin Rostock, Zentrum für Innere Medizin, Abteilung Kardiologie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
transcatheter aortic valve Implantation (TAVI), renal dysfunction defined as Serum creatinine >123,76 µmol/l or GFR <60 ml/min/1,73m² calculated with CKD-EPI formula, informed consent
Exclusion Criteria
Dialysis
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of contrast-induced nephropathy defined as increase of Serum creatinine = 44 µmol/l or = 25% above baseline within 48 h
- Secondary Outcome Measures
Name Time Method maximum increase of serum creatinine, Serum Cystatine C and urinary NGAL, dialysis and death